Login to Your Account



Clinic roundup


Thursday, May 8, 2014
Epizyme Inc., of Cambridge, Mass., said it started a phase Ib open-label study of EPZ-5676 in pediatric patients with acute leukemias bearing a rearrangement of the MLL gene (MLL-r).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription